Fermenta Biotech reports strong H1/FY26 performance, revenue up 57%

Fermenta Biotech Limited announced a significant turnaround in its H1/FY26 financial performance. Consolidated revenue reached INR 280.7 crore, a 57% year-over-year increase. EBITDA surged by 173% to INR 69.1 crore, and profit after tax (PAT) saw a 664% rise to INR 39.6 crore. This growth was primarily fueled by the human nutrition segment, which experienced a 74% increase in volumes.

The company's German toll manufacturing subsidiary reported revenue of INR 34.3 crore, up 194% year-over-year, contributing INR 7.7 crore in EBITDA. Cost management efforts were evident, with raw material costs stable at 38% of revenue and manufacturing expenses improving to 11% from 15% in FY25. Finance costs also decreased to 2% of revenue from 3% in FY25, boosting profitability.

Fermenta Biotech also highlighted strategic developments, including the formal grant of a patent for its plant-based Vitamin D3 manufacturing process in September 2025. Additionally, the Board approved the transfer of its 'Environment Division' to a wholly owned subsidiary for INR 19 crore, effective October 1, 2025. The company's cash flow statement showed a positive net cash flow of INR 3 crore, indicating enhanced liquidity and financial discipline.